Literature DB >> 1706399

Complement-mediated lysis of Trypanosoma cruzi trypomastigotes by human anti-alpha-galactosyl antibodies.

I C Almeida1, S R Milani, P A Gorin, L R Travassos.   

Abstract

Antibodies that lyse trypomastigotes in a complement-mediated reaction are believed to be the main participants in the protection against virulent Trypanosoma cruzi. Antibodies with a specificity for alpha-galactosyl-containing determinants--generally called antiGal--were studied to determine their role in the lysis of trypomastigote forms. The titers of antiGal markedly increase in Chagas's disease. In the present study we demonstrate binding of this antibody to T. cruzi and the complement-mediated lysis of trypomastigotes by antiGal. Lysis of metacyclic trypomastigotes by whole Chagasic (Ch) serum or isolated antiGal fractions was equally inhibited by alpha- but not by beta-galactosides. Most of the lytic power of the Ch antiGal as well as of the whole Ch serum was removed by absorption on Synsorb-linked Gal alpha 1, 3Gal beta 1, 4GlcNAc followed by rabbit erythrocyte absorption. The Ch antiGal had a lower affinity for melibiose bound to agarose than for the trisaccharide linked to Synsorb, and was several times more effective in the immunolysis of trypomastigotes than the corresponding antiGal from normal human serum. Lytic antibodies were partly absorbed by Serratia marcescens but not by Escherichia coli O111. A human volunteer immunized with an S. marcescens vaccine elicited a specific antiGal response that was lytic to trypomastigotes (70% lysis). We suggest that in vivo high-affinity antiGal antibody clones, as occur in Ch patients, may significantly contribute to the destruction of the parasite, whereas low-affinity antiGal clones are much less effective in the protection against T. cruzi infection.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1706399

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  53 in total

1.  Vesicle and vesicle-free extracellular proteome of Paracoccidioides brasiliensis: comparative analysis with other pathogenic fungi.

Authors:  Milene C Vallejo; Ernesto S Nakayasu; Alisson L Matsuo; Tiago J P Sobreira; Larissa V G Longo; Luciane Ganiko; Igor C Almeida; Rosana Puccia
Journal:  J Proteome Res       Date:  2012-02-14       Impact factor: 4.466

2.  A synthetic peptide from Trypanosoma cruzi mucin-like associated surface protein as candidate for a vaccine against Chagas disease.

Authors:  Carylinda Serna; Joshua A Lara; Silas P Rodrigues; Alexandre F Marques; Igor C Almeida; Rosa A Maldonado
Journal:  Vaccine       Date:  2014-04-30       Impact factor: 3.641

Review 3.  Significance of the evolutionary α1,3-galactosyltransferase (GGTA1) gene inactivation in preventing extinction of apes and old world monkeys.

Authors:  Uri Galili
Journal:  J Mol Evol       Date:  2014-10-15       Impact factor: 2.395

4.  Synthesis of Galα(1,3)Galβ(1,4)GlcNAcα-, Galβ(1,4)GlcNAcα- and GlcNAc-containing neoglycoproteins and their immunological evaluation in the context of Chagas disease.

Authors:  Nathaniel S Schocker; Susana Portillo; Carlos R N Brito; Alexandre F Marques; Igor C Almeida; Katja Michael
Journal:  Glycobiology       Date:  2015-09-18       Impact factor: 4.313

5.  O-glycosidically linked N-acetylglucosamine-bound oligosaccharides from glycoproteins of Trypanosoma cruzi.

Authors:  J O Previato; C Jones; L P Gonçalves; R Wait; L R Travassos; L Mendonça-Previato
Journal:  Biochem J       Date:  1994-07-01       Impact factor: 3.857

6.  Trypanosoma cruzi infection enhances polyreactive antibody response in an acute case of human Chagas' disease.

Authors:  M R Grauert; M Houdayer; M Hontebeyrie-Joskowciz
Journal:  Clin Exp Immunol       Date:  1993-07       Impact factor: 4.330

7.  Inefficient complement system clearance of Trypanosoma cruzi metacyclic trypomastigotes enables resistant strains to invade eukaryotic cells.

Authors:  Igor Cestari; Marcel I Ramirez
Journal:  PLoS One       Date:  2010-03-16       Impact factor: 3.240

Review 8.  Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody.

Authors:  U Galili
Journal:  Springer Semin Immunopathol       Date:  1993

9.  Use of a 24-kilodalton Trypanosoma cruzi recombinant protein to monitor cure of human Chagas' disease.

Authors:  G M Krautz; L M Galvão; J R Cançado; A Guevara-Espinoza; A Ouaissi; A U Krettli
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

10.  Anti-alpha-galactosyl immunoglobulin A (IgA), IgG, and IgM in human secretions.

Authors:  R M Hamadeh; U Galili; P Zhou; J M Griffiss
Journal:  Clin Diagn Lab Immunol       Date:  1995-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.